Citations

Citations to this article as recorded by  

• Integrating In Vitro Analytics for Improved Antibody–Drug Conjugate Candidate Selection
  Virginia del Solar, Ali Saleh, Annarita Di Tacchio, Lena Sokol Becciolini, Gyoung Dong Kang, Bianka Jackowska, Yan Hu, Chao Gong, Angel Zhang, Leigh Hostetler, Maximilliam Lee, Akbar H. Khan, Abhisek Mitra, Mahammad Ahmed, David Tickle, Balakumar Vijayakr
  Cancers.2026; 18(1): 164.     CrossRef
• Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure
  B. Adhikari, M.R. Litzow, A.L. Dias
  Blood Reviews.2026; 77: 101391.     CrossRef
• CD56bright cytokine-induced memory-like NK cells and NK-cell engagers synergize against non-small cell lung cancer cancer-stem cells
  Maria L Guevara Lopez, Ann Gebo, Monica Parodi, Stefano Persano, Josephine Maus-Conn, Maria Cristina Mingari, Fabrizio Loiacono, Paola Orecchia, Simona Sivori, Claudia Cantoni, Marco Gentili, Federica Facchinetti, Riccardo Ferracini, Daniel A Vallera, Mar
  Journal for ImmunoTherapy of Cancer.2025; 13(2): e010205.     CrossRef
• Adjusting the scope of natural killer cells in cancer therapy
  Zihen Shen, Xiangpeng Meng, Jai Rautela, Michael Chopin, Nicholas D. Huntington
  Cellular & Molecular Immunology.2025; 22(7): 699.     CrossRef
• Beyond CAR-T: Engineered NK cell therapies (CAR-NK, NKCEs) in next-generation cancer immunotherapy
  Fenghao Zhang, Hamed Soleimani Samarkhazan, Zahra Pooraskari, Alireza Bayani
  Critical Reviews in Oncology/Hematology.2025; 214: 104912.     CrossRef
• An IL-15-modified NKp30×HER2 trispecific NK cell engager enhances NK cell activation and tumor cell killing
  Yaping Cheng, Quanxiao Li, Yu Kong, Ailing Huang, Zhenlin Yang, Tianlei Ying, Yanling Wu
  Journal of Leukocyte Biology.2025;[Epub]     CrossRef
• A nanobody-based tri-specific NK cell engager targeting CD5 triggers antitumor immunity
  Chen Yang, Ping Wang, Mingjun Yang, Huaqing Lu, Qizhong Lu, Zongliang Zhang, Zeng Wang, Zhixiong Zhu, Hexian Li, Wanqin Zeng, Zhengyu Yu, Meng Li, Lizhou Zhao, Bo Ling, Wei Wang, Hai Yi, Yisong Xiong, Ting Niu, Aiping Tong
  Cell Reports Medicine.2025; 6(10): 102409.     CrossRef
• Engineered natural killer cells for cancer therapy
  Alexander Biederstädt, Katayoun Rezvani
  Cancer Cell.2025; 43(11): 1987.     CrossRef
• New immune cell engagers for cancer immunotherapy
  Aurore Fenis, Olivier Demaria, Laurent Gauthier, Eric Vivier, Emilie Narni-Mancinelli
  Nature Reviews Immunology.2024; 24(7): 471.     CrossRef
• Natural killer cell therapies
  Eric Vivier, Lucas Rebuffet, Emilie Narni-Mancinelli, Stéphanie Cornen, Rob Y. Igarashi, Valeria R. Fantin
  Nature.2024; 626(8000): 727.     CrossRef
• Tri-specific killer engager: unleashing multi-synergic power against cancer
  Peeranut Winidmanokul, Aussara Panya, Seiji Okada
  Exploration of Targeted Anti-tumor Therapy.2024; 5(2): 432.     CrossRef
• Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases
  Camille Rolin, Jacques Zimmer, Carole Seguin-Devaux
  Cellular & Molecular Immunology.2024; 21(7): 643.     CrossRef
• Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives
  Magdalena Rados, Anna Landegger, Lukas Schmutzler, Kimberlie Rabidou, Sabine Taschner-Mandl, Irfete S. Fetahu
  Cancer and Metastasis Reviews.2024; 43(4): 1401.     CrossRef
• Implications of glycosylation for the development of selected cytokines and their derivatives for medical use
  Giulia Scapin, Ece Cagdas, Lise Marie Grav, Nathan E Lewis, Steffen Goletz, Lise Hafkenscheid
  Biotechnology Advances.2024; 77: 108467.     CrossRef
• Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
  An Zhu, Yu Bai, Yanyang Nan, Dianwen Ju
  Clinical and Translational Medicine.2024;[Epub]     CrossRef
• Emerging Antibodies in Cancer Therapy
  Yaping Sun, Jian Xu
  Advanced NanoBiomed Research.2023;[Epub]     CrossRef
• Mapping the interplay between NK cells and HIV: therapeutic implications
  Renee R Anderko, Robbie B Mailliard
  Journal of Leukocyte Biology.2023; 113(2): 109.     CrossRef
• Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody
  Julia Harwardt, Stefania C. Carrara, Jan P. Bogen, Katrin Schoenfeld, Julius Grzeschik, Björn Hock, Harald Kolmar
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
  Xinghui Xiao, Ying Cheng, Xiaodong Zheng, Yuhang Fang, Yu Zhang, Rui Sun, Zhigang Tian, Haoyu Sun
  Frontiers in Immunology.2023;[Epub]     CrossRef
• NK cell defects: implication in acute myeloid leukemia
  Selma Z. D’Silva, Meenakshi Singh, Andrea S. Pinto
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
  Eunju Shin, Seong Ho Bak, Taeho Park, Jin Woo Kim, Suk-Ran Yoon, Haiyoung Jung, Ji-Yoon Noh
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy
  Minchuan Zhang, Kong-Peng Lam, Shengli Xu
  Frontiers in Immunology.2023;[Epub]     CrossRef
• Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
  Tian Huan, Bugao Guan, Hongbo Li, Xiu Tu, Chi Zhang, Bin Tang
  Human Vaccines & Immunotherapeutics.2023;[Epub]     CrossRef
• Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma
  Titas Banerjee, Anusha Vallurupalli
  Current Problems in Cancer.2022; 46(1): 100825.     CrossRef
• The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy
  Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao, Zhigang Tian
  Cellular & Molecular Immunology.2022; 19(2): 192.     CrossRef
• Engineering interferons and interleukins for cancer immunotherapy
  Patrick G. Holder, Shion A. Lim, Christine S. Huang, Preeti Sharma, Yavuz S. Dagdas, Beyza Bulutoglu, Jonathan T. Sockolosky
  Advanced Drug Delivery Reviews.2022; 182: 114112.     CrossRef
• iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting
  Benjamin H. Goldenson, Pooja Hor, Dan S. Kaufman
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy
  Wanze Zhang, Zhenghua Zhao, Fan Li
  Molecular Immunology.2022; 144: 58.     CrossRef
• Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
  Dain Moon, Nara Tae, Yunji Park, Seung-Woo Lee, Dae Hee Kim
  Immune Network.2022;[Epub]     CrossRef
• Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
  Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
  Nature Reviews Drug Discovery.2022; 21(8): 559.     CrossRef
• Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
  Mubin Tarannum, Rizwan Romee, Roman M. Shapiro
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Bispecific antibodies for immune cell retargeting against cancer
  Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang, Javier Chaparro-Riggers
  Expert Opinion on Biological Therapy.2022; 22(8): 965.     CrossRef
• The Dynamic Role of NK Cells in Liver Cancers: Role in HCC and HBV Associated HCC and Its Therapeutic Implications
  Muhammad Sajid, Lianxin Liu, Cheng Sun
  Frontiers in Immunology.2022;[Epub]     CrossRef
• Emerging Trends in Immunotherapy for Cancer
  Alok K. Mishra, Amjad Ali, Shubham Dutta, Shahid Banday, Sunil K. Malonia
  Diseases.2022; 10(3): 60.     CrossRef
• Drug-Tolerant Persister Cells in Cancer Therapy Resistance
  Pavan Kumar Dhanyamraju, Todd D. Schell, Shantu Amin, Gavin P. Robertson
  Cancer Research.2022; 82(14): 2503.     CrossRef
• Natural killer cells in antitumour adoptive cell immunotherapy
  Tamara J. Laskowski, Alexander Biederstädt, Katayoun Rezvani
  Nature Reviews Cancer.2022; 22(10): 557.     CrossRef
• TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
  Michael F Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Behiye Kodal, Yvette Soignier, Peter Hinderlie, Joshua T Walker, Todd R Lenvik, Melissa A Geller, Jeffrey S Miller, Martin Felices
  Journal for ImmunoTherapy of Cancer.2022; 10(9): e004725.     CrossRef
• The soldiers needed to be awakened: Tumor-infiltrating immune cells
  Wang Yaping, Wang Zhe, Chu Zhuling, Li Ruolei, Fan Pengyu, Guo Lili, Ji Cheng, Zhang Bo, Liu Liuyin, Hou Guangdong, Wang Yaoling, Hou Niuniu, Ling Rui
  Frontiers in Genetics.2022;[Epub]     CrossRef
• Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
  Xinyu Wu, Sandro Matosevic
  Molecular Therapy - Oncolytics.2022; 27: 224.     CrossRef
• Multiplexed engineering and precision gene editing in cellular immunotherapy
  Alexander Biederstädt, Gohar Shahwar Manzar, May Daher
  Frontiers in Immunology.2022;[Epub]     CrossRef
• NK cells and ILCs in tumor immunotherapy
  Simona Sivori, Daniela Pende, Linda Quatrini, Gabriella Pietra, Mariella Della Chiesa, Paola Vacca, Nicola Tumino, Francesca Moretta, Maria Cristina Mingari, Franco Locatelli, Lorenzo Moretta
  Molecular Aspects of Medicine.2021; 80: 100870.     CrossRef
• Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy
  Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise, Daniel Olive
  Journal of Leukocyte Biology.2021; 109(6): 1071.     CrossRef
• Cancer stem cells and strategies for targeted drug delivery
  Jin Cao, Shubhmita Bhatnagar, Jiawei Wang, Xueyong Qi, Swayam Prabha, Jayanth Panyam
  Drug Delivery and Translational Research.2021; 11(5): 1779.     CrossRef
• The role of natural killer cell in gastrointestinal cancer: killer or helper
  Feixue Wang, Jennie Ka Ching Lau, Jun Yu
  Oncogene.2021; 40(4): 717.     CrossRef
• Next-Generation Immunotherapies to Improve Anticancer Immunity
  Yaoyao Shi, Katarzyna Tomczak, June Li, Joshua K. Ochieng, Younghee Lee, Cara Haymaker
  Frontiers in Pharmacology.2021;[Epub]     CrossRef
• Engineered Multifunctional Nano‐ and Biological Materials for Cancer Immunotherapy
  Anthony Brouillard, Nilesh Deshpande, Ashish A. Kulkarni
  Advanced Healthcare Materials.2021;[Epub]     CrossRef
• Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
  Cristina Capuano, Chiara Pighi, Simone Battella, Davide De Federicis, Ricciarda Galandrini, Gabriella Palmieri
  Cancers.2021; 13(10): 2500.     CrossRef
• Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments
  Olivier Demaria, Laurent Gauthier, Guilhaume Debroas, Eric Vivier
  European Journal of Immunology.2021; 51(8): 1934.     CrossRef
• Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies
  Gihoon You, Jonghwa Won, Yangsoon Lee, Dain Moon, Yunji Park, Sang Hoon Lee, Seung-Woo Lee
  Vaccines.2021; 9(7): 724.     CrossRef
• Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy
  Shee Kwan Phung, Jeffrey S. Miller, Martin Felices
  Molecular Diagnosis & Therapy.2021; 25(5): 577.     CrossRef
• Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
  Guangyu Lian, Thomas Shiu-Kwong Mak, Xueqing Yu, Hui-Yao Lan
  International Journal of Molecular Sciences.2021; 23(1): 164.     CrossRef
• Targeting Natural Killer Cells for Tumor Immunotherapy
  Cai Zhang, Yuan Hu, Chongdeng Shi
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
  Aviad Ben-Shmuel, Guy Biber, Mira Barda-Saad
  Frontiers in Immunology.2020;[Epub]     CrossRef
• Boosting Cytotoxic Antibodies against Cancer
  Laurent Gauthier, Eric Vivier
  Cell.2020; 180(5): 822.     CrossRef
• Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
  Margaux Lejeune, Murat Cem Köse, Elodie Duray, Hermann Einsele, Yves Beguin, Jo Caers
  Frontiers in Immunology.2020;[Epub]     CrossRef
• NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
  Daniel A. Vallera, Soldano Ferrone, Behiye Kodal, Peter Hinderlie, Laura Bendzick, Brianna Ettestad, Caroline Hallstrom, Nicholas A. Zorko, Arpit Rao, Naomi Fujioka, Charles J. Ryan, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
  Cancers.2020; 12(9): 2659.     CrossRef
• Exploiting NK Cell Surveillance Pathways for Cancer Therapy
  Alexander Barrow, Marco Colonna
  Cancers.2019; 11(1): 55.     CrossRef
• Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
  Gaurav Nayyar, Yaya Chu, Mitchell S. Cairo
  Frontiers in Oncology.2019;[Epub]     CrossRef
• Natural Killer Cells in Cancer Immunotherapy
  Jeffrey S. Miller, Lewis L. Lanier
  Annual Review of Cancer Biology.2019; 3(1): 77.     CrossRef
• Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL
  Martin Felices, Behiye Kodal, Peter Hinderlie, Michael F. Kaminski, Sarah Cooley, Daniel J. Weisdorf, Daniel A. Vallera, Jeffrey S. Miller, Veronika Bachanova
  Blood Advances.2019; 3(6): 897.     CrossRef
• Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses
  Mathieu J.F. Crupi, John C. Bell, Ragunath Singaravelu
  Stem Cells.2019; 37(6): 716.     CrossRef
• Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
  Laurent Gauthier, Ariane Morel, Nadia Anceriz, Benjamin Rossi, Audrey Blanchard-Alvarez, Gwendoline Grondin, Sylvia Trichard, Cédric Cesari, Melody Sapet, Frédéric Bosco, Hélène Rispaud-Blanc, Franceline Guillot, Stéphanie Cornen, Alain Roussel, Béatrice
  Cell.2019; 177(7): 1701.     CrossRef
• Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity
  Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Susanne Wingert, Thorsten Ross, Thomas Müller, Ute Schniegler-Mattox, Torsten Haneke, Erich Rajkovic, Joachim Koch, Martin Treder, Michael Tesar
  mAbs.2019; 11(5): 899.     CrossRef
• T Cell–Activating Bispecific Antibodies in Cancer Therapy
  Asaad Trabolsi, Artavazd Arumov, Jonathan H Schatz
  The Journal of Immunology.2019; 203(3): 585.     CrossRef
• Les anticorps etscaffoldbispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires
  Patrick Chames, Thierry Wurch
  médecine/sciences.2019; 35(12): 1072.     CrossRef
• Emerging trends in bispecific antibody and scaffold protein therapeutics
  Petra Verdino, Shane Atwell, Stephen J Demarest
  Current Opinion in Chemical Engineering.2018; 19: 107.     CrossRef
• Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
  Sarah Cooley, Peter Parham, Jeffrey S. Miller
  Blood.2018; 131(10): 1053.     CrossRef
• Bispecific antibodies in cancer immunotherapy
  Eva Dahlén, Niina Veitonmäki, Per Norlén
  Therapeutic Advances in Vaccines and Immunotherapy.2018; 6(1): 3.     CrossRef
• Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics
  Martin Dalziel, Stephen A Beers, Mark S Cragg, Max Crispin
  Glycobiology.2018; 28(9): 697.     CrossRef
• The role of CD133 in cancer: a concise review
  Paige M. Glumac, Aaron M. LeBeau
  Clinical and Translational Medicine.2018;[Epub]     CrossRef
• Advances and challenges in therapeutic monoclonal antibodies drug development
  Mariana Lopes dos Santos, Wagner Quintilio, Tania Maria Manieri, Lilian Rumi Tsuruta, Ana Maria Moro
  Brazilian Journal of Pharmaceutical Sciences.2018;[Epub]     CrossRef
• Redirecting T cells to hematological malignancies with bispecific antibodies
  Mireya Paulina Velasquez, Challice L. Bonifant, Stephen Gottschalk
  Blood.2018; 131(1): 30.     CrossRef
• Developmental and Functional Control of Natural Killer Cells by Cytokines
  Yang Wu, Zhigang Tian, Haiming Wei
  Frontiers in Immunology.2017;[Epub]     CrossRef
• Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy
  Zachary B. Davis, Daniel A. Vallera, Jeffrey S. Miller, Martin Felices
  Seminars in Immunology.2017; 31: 64.     CrossRef

Citations

Citations to this article as recorded by  

• Microwave‐Promoted Multicomponent Synthesis Catalyzed by DABCO, Anti‐Esophageal Cancer, Apoptotic Morphology, Kinetic Mechanism, and Computational Studies of New Pyrrole Derivatives
  Ahmed Majeed Jassem, Bahjat A. Saeed
  ChemistrySelect.2026;[Epub]     CrossRef
• Arachidonic acid metabolism as a novel pathogenic factor in gastrointestinal cancers
  Weiqin Lu, Aihemaitijiang Aihaiti, Paziliya Abudukeranmu, Yajun Liu, Huihui Gao
  Molecular and Cellular Biochemistry.2025; 480(2): 1225.     CrossRef
• Synthesis and biological evaluation of novel 2-morpholino-4-anilinoquinoline derivatives as antitumor agents against HepG2 cell line
  Ahmed Al-Sheikh, Malak A. Jaber, Hana'a Khalaf, Nour AlKhawaja, Duaa Abuarqoub
  RSC Advances.2024; 14(5): 3304.     CrossRef
• Natural alkaloids as potential treatments for esophageal squamous-cell carcinoma: A comprehensive review
  Eugene Jamot Ndebia, Gabriel Tchuente Kamsu
  Gastroenterology & Endoscopy.2024; 2(3): 131.     CrossRef
• Downregulation of chemokine (C‑C motif) ligand 5 induced by a novel 8‑hydroxyquinoline derivative (91b1) suppresses tumor invasiveness in esophageal carcinoma
  Johnny Tang, Dessy Chan, Po-Yee Chung, Yijiang Liu, Alfred Lam, Simon Law, Wolin Huang, Albert Chan, Kim-Hung Lam, Yuanyuan Zhou
  International Journal of Molecular Medicine.2024;[Epub]     CrossRef
• Peroxisome proliferator-activated receptors regulate the progression and treatment of gastrointestinal cancers
  Min Zhang, Shujie He
  Frontiers in Pharmacology.2023;[Epub]     CrossRef
• Roles of Nuclear Receptors in Esophageal Cancer
  Lihao Deng, Jiaxuan Liu, Wei-Dong Chen, Yan-Dong Wang
  Current Pharmaceutical Biotechnology.2023; 24(12): 1489.     CrossRef
• Synthesis and biological activities of new phthalimide and thiazolidine derivatives
  Flaviana A. Santos, Marcel L. Almeida, Vitor A. S. Silva, Douglas C. F. Viana, Michelly C. Pereira, André S. L. Lucena, Maira G. R. Pitta, Marina R. Galdino-Pitta, Moacyr J. B. de Melo Rêgo, Ivan da Rocha Pitta
  Medicinal Chemistry Research.2022; 31(1): 108.     CrossRef
• Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer
  David Jay Wilson, Raymond N. DuBois
  Cancer Prevention Research.2022; 15(6): 355.     CrossRef
• The Anticancer Effect of a Novel Quinoline Derivative 91b1 through Downregulation of Lumican
  Yuanyuan Zhou, Zhongguo Zhou, Dessy Chan, Po yee Chung, Yongqi Wang, Albert Sun chi Chan, Simon Law, Kim hung Lam, Johnny Cheuk On Tang
  International Journal of Molecular Sciences.2022; 23(21): 13181.     CrossRef
• Synthesis and biological evaluations of N′-substituted methylene-4-(quinoline-4-amino) benzoylhydrazides as potential anti-hepatoma agents
  Baicun Li, Feifeng Zhu, Fengming He, Qingqing Huang, Xiaoguang Liu, Tong Wu, Taige Zhao, Yingkun Qiu, Zhen Wu, Yuhua Xue, Meijuan Fang
  Bioorganic Chemistry.2020; 96: 103592.     CrossRef
• Feasibility of Repurposing Clioquinol for Cancer Therapy
  Raheel Khan, Harras Khan, Yassen Abdullah, Q. Ping Dou
  Recent Patents on Anti-Cancer Drug Discovery.2020; 15(1): 14.     CrossRef
• DFIQ, a Novel Quinoline Derivative, Shows Anticancer Potential by Inducing Apoptosis and Autophagy in NSCLC Cell and In Vivo Zebrafish Xenograft Models
  Hurng-Wern Huang, Yung-Ding Bow, Chia-Yih Wang, Yen-Chun Chen, Pei-Rong Fu, Kuo-Feng Chang, Tso-Wen Wang, Chih-Hua Tseng, Yeh-Long Chen, Chien-Chih Chiu
  Cancers.2020; 12(5): 1348.     CrossRef
• Reverse Screening Methods to Search for the Protein Targets of Chemopreventive Compounds
  Hongbin Huang, Guigui Zhang, Yuquan Zhou, Chenru Lin, Suling Chen, Yutong Lin, Shangkang Mai, Zunnan Huang
  Frontiers in Chemistry.2018;[Epub]     CrossRef
• The roles of the COX2/PGE2/EP axis in therapeutic resistance
  Dali Tong, Qiuli Liu, Lin-ang Wang, Qiubo Xie, Jian Pang, Yiqiang Huang, Luofu Wang, Gaolei Liu, Dianzheng Zhang, Weihua Lan, Jun Jiang
  Cancer and Metastasis Reviews.2018; 37(2-3): 355.     CrossRef
• Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma
  Dessy Chan, Yuanyuan Zhou, Chung Hin Chui, Kim Hung Lam, Simon Law, Albert Sun-chi Chan, Xingshu Li, Alfred King-yin Lam, Johnny Cheuk On Tang
  Cells.2018; 7(10): 143.     CrossRef
• Targeting DNA Binding for NF-κB as an Anticancer Approach in Hepatocellular Carcinoma
  Po Chung, Pik Lam, Yuanyuan Zhou, Jessica Gasparello, Alessia Finotti, Adriana Chilin, Giovanni Marzaro, Roberto Gambari, Zhaoxiang Bian, Wai Kwok, Wai Wong, Xi Wang, Alfred Lam, Albert Chan, Xingshu Li, Jessica Ma, Chung Chui, Kim Lam, Johnny Tang
  Cells.2018; 7(10): 177.     CrossRef